In patients with HER2-positive and HoR-positive breast cancer in whom comorbidities, personal preferences, or functional status limit the use of chemotherapy, endocrine therapy—such as an aromatase inhibitor—combined with HER2-targeted therapy (trastuzumab plus pertuzumab) is suggested (expert recommendation). Here, CYP19A1 is linked to breast cancer.